Ann: Quarterly Activities and Cashflow Report, page-58

You know I am not worried about XPED having to have better products as Beta vs VHS always good tale of not having to have best product to have commercial success..

But alas that is where concern around XPED comes to the fore as lack of commercial and IT strategic sales capabilities makes it so much harder than always would be for small tech stock.

As has always the case usual lots of irons in the fire (and new irons in the fire as many past MOU's achieved and come to nothing) and we are still waiting for proof one can be commercially successful. JCT made some traction but still not yet profitable....

For my mind the Vital Xense data centre study with $2m grant is very interesting and could be game changer but again still too early to determine that.

Still think good speculative punt at this point down here on that quarterly but certainly only warrants small punt and not a stock to put the house on.